Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared on LinkedIn:
“ESMO 2025 Breast Cancer Update: DESTINY Revolution Continues
PRESIDENTIAL SYMPOSIUM I – The Game Changers. Saturday Oct 18, 16:30-18:15 | Berlin Auditorium (Hub 27)
DESTINY-Breast11 (291O) – Nadia Harbeck, Neoadjuvant T-DXd transforming HER2+ early breast cancer standards, DESTINY-Breast05 (LBA1) – Charles Geyer, T-DXd vs T-DM1 head-to-head in high-risk adjuvant setting.
PROFFERED PAPERS – Major Updates. Friday Oct 17, 14:00-15:30 | Munich Auditorium
The CDK4/6 Landmark Moment
• LBA13: MONARCH-E Primary OS Results (Stephen Johnston)
• LBA14: NATALEE 5-Year Outcomes (John Crown)
• Plus: SOLTIRIBOLARIS, POSITIVE 5-year data, Low-dose pembrolizumab TNBC
Saturday-Sunday Sessions
Metastatic Breakthroughs
• LBA18: DESTINY-Breast09 subgroup analyses
• LBA20: ASCENT-03 (SG vs chemo in untreated PD-L1- TNBC)
• LBA17,23,24: VIKTORIA-1, OptiTROP-Breast02, Trastuzumab botidotinWhy This Weekend Matters
DESTINY completes HER2+ transformation across all stages:
• Neoadjuvant (DB11) + Adjuvant (DB05) + Metastatic (DB09) = Complete paradigm shift
CDK4/6 milestone data:
• First MONARCH-E overall survival results
• NATALEE long-term outcomes solidifying broad adjuvant use
The next future of both HER2+ and HR+ breast cancer treatment will be defined in Berlin.”
More posts featuring Armando Orlandi.